- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02734277
Estudio de extensión de diabetes tipo 1 (T1DES)
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).
This observational study will:
- follow participants to determine how long they continue to produce insulin, and
- will also assess how changes in the immune system over time relate to the ability to produce insulin.
This information could help design better therapies for type 1 diabetes in the future.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Depending upon a participant's level of insulin production, participation may be as short as one return visit or a maximum of five years. Evaluation visits will include:
- Overall health assessments
- Blood and urine collections
- Mixed meal tolerance test (MMTTs) for certain participants, per protocol.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
San Francisco, California, Estados Unidos, 94143
- Reclutamiento
- UCSF School of Medicine
-
Contacto:
- Rebecca Wesch
- Número de teléfono: 415-476-5984
- Correo electrónico: rebecca.wesch@ucsf.edu
-
Investigador principal:
- Stephen Gitelman, MD
-
Stanford, California, Estados Unidos, 94305
- Reclutamiento
- Stanford University
-
Contacto:
- Trudy Esrey
- Número de teléfono: 650-498-4450
- Correo electrónico: tesrey@stanford.edu
-
Investigador principal:
- Darrell Wilson, MD
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- University of Colorado School of Medicine: Barbara Davis Center for Diabetes
-
Investigador principal:
- Peter Gottlieb, MD
-
Contacto:
- Mara Kinney
- Número de teléfono: (303) 724-8272
- Correo electrónico: MARA.KINNEY@ucdenver.edu
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06519
- Terminado
- Yale University
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Retirado
- Emory University
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Reclutamiento
- Indiana University Riley Hospital for Children
-
Contacto:
- Ellie Ryan
- Número de teléfono: 317-278-7037
- Correo electrónico: elmryan@iu.edu
-
Contacto:
- Maria Spall
- Número de teléfono: 317-278-7034
- Correo electrónico: malnicho@iu.edu
-
Investigador principal:
- Linda DiMeglio, MD, MPH
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Reclutamiento
- University of Iowa Health Care Division of Pediatric Endocrinology
-
Contacto:
- Joanne Cabbage
- Número de teléfono: 319-356-4035
- Correo electrónico: joanne-cabbage@uiowa.edu
-
Investigador principal:
- Michael Tansey, MD
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Joslin Diabetes Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 888-813-8669
- Correo electrónico: T1DTrials@joslin.harvard.edu
-
Investigador principal:
- Jason Gaglia, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55454
- Reclutamiento
- University of Minnesota
-
Contacto:
- Anne Street
- Número de teléfono: 612-625-9709
- Correo electrónico: stree065@umn.edu
-
Investigador principal:
- Antoinette Moran, MD
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- Terminado
- Children's Mercy Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57104
- Terminado
- Sanford Research
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98101
- Reclutamiento
- Benaroya Research Institute
-
Investigador principal:
- Sandra Lord, MD
-
Contacto:
- Katie Bennett
- Número de teléfono: (206) 341-8945
- Correo electrónico: kbennett@benaroyaresearch.org
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Former participants in Immune Tolerance Network (ITN) new-onset Type 1 Diabetes Mellitus (T1DM) studies with immunomodulatory agents as the intervention.
Descripción
Inclusion Criteria:
- Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
- Ability to sign informed consent/assent (as applicable for children).
Exclusion Criteria:
- Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
- Inability to comply with the study visit schedule and required assessments.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Group 1: Detectable C-peptide by MMTT
Participants with detectable C-peptide at their:
Detectable C-peptide is defined as a value above the lower limit of detection. |
|
Group 2:Undetectable C-peptide by MMTT
Participants without detectable C-peptide at their:
Undetectable C-peptide is defined as a value below the lower limit of detection. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC)
Periodo de tiempo: Baseline (Visit 0) to Month 60 (Year 5)
|
Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC). C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. Detectable C-peptide is defined as any value during a MMTT of ≥0.15 ng/mL. |
Baseline (Visit 0) to Month 60 (Year 5)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Insulin Use in Units per Kilogram Body Weight Per Day
Periodo de tiempo: Baseline (Visit 0) to Month 60 (Year 5)
|
The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Change in HbA1C
Periodo de tiempo: Baseline (Visit 0) to Month 60 (Year 5)
|
Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Count of Participant-Reported Major Hypoglycemic Events
Periodo de tiempo: Baseline (Visit 0) to Month 60 (Year 5)
|
Major hypoglycemic events are defined as a glucose concentration <55 mg/dL (grades 2-5, NCI-CTCAE version 4.03), or clinically: involving seizure(s) or involving loss of consciousness (coma), or requiring assistance from another individual in order to recover. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Time to Undetectable C-Peptide
Periodo de tiempo: Baseline (Visit 0) to Month 60 (Year 5)
|
To assess the longevity of beta cell function, time to undetectable C-peptide will be evaluated using Kaplan-Meier survival estimates. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Frequency of Grade 3 or Higher Adverse Events (AEs) of Interest
Periodo de tiempo: Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Severity of Grade 3 or Higher Adverse Events (AEs) of Interest
Periodo de tiempo: Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Silla de estudio: Linda A. DiMeglio, MD, MPH,MA, Riley Hospital for Children at Indiana University Health
Publicaciones y enlaces útiles
Publicaciones Generales
- Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8.
- Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.
- Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Enfermedades metabólicas
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Trastornos del metabolismo de la glucosa
- Diabetes mellitus
- Hiperinsulinismo
- Hiperglucemia
- Enfermedades Nutricionales y Metabólicas
- Diabetes Mellitus, Tipo 1
- Resistencia a la insulina
- Intolerante a la glucosa
Otros números de identificación del estudio
- DAIT ITN066AI
- NIAID CRMS ID#: 20722 (Otro identificador: DAIT NIAID)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.
Marco de tiempo para compartir IPD
After completion of the study.
Criterios de acceso compartido de IPD
Will be available to the public.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .